UK Leads European Research Programme with £10M Investment

The UK has made its first substantial commitment to a major emerging pan-European science project with a £10M investment by the Biotechnology and Biological Sciences Research Council (BBSRC). BBSRC has awarded funding to the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI), based at Hinxton near Cambridge, to permit a dramatic increase in the institute's data storage and handling capacity. The funding is the first step in developing the existing data resources and IT infrastructure of EMBL-EBI towards its planned role as the central hub of the emerging European Life-Science Infrastructure for Biological Information (ELIXIR), placing the UK at the forefront of this multinational initiative. The estimated total cost of establishing ELIXIR is significantly more than £200M.

Modern bioscience research, including the new generation of high through-put sequencing technologies, generates huge amounts of data. In order to use the data efficiently and to accelerate bioscience advances, such as the development of new drugs and therapies or higher yielding crops, scientists require better ways to deal with this avalanche of information.

ELIXIR is an initiative involving 32 partners from 13 countries aimed at establishing a sustainably funded infrastructure for biological information in Europe. It will support life science research and its applications to medicine, agriculture and food security, the environment, the bio-industries and society.

The UK's involvement in ELIXIR is supported by BBSRC, MRC, NERC and the Wellcome Trust.

EMBL-EBI Director and ELIXIR coordinator, Professor Janet Thornton, said: "The UK's decision to invest in ELIXIR is an important milestone in creating the infrastructure for biological information in Europe. The EBI will form the hub of a network of ELIXIR nodes that will empower European science at the interface of biology, computing and data management - one of the most vibrant areas of contemporary research. In particular it means that we will be able to implement next-generation datahandling and storage solutions, which will be able to cope with the flood of biological data and fuel future developments in basic biology, medicine, agriculture and environmental sciences."

Professor Doug Kell, Chief Executive of BBSRC, said: "Biology is an information science that is rich in data. UK science funders and EMBL-EBI are committed to ensuring that our researchers can use the latest computational technologies to store, access and analyse the huge amounts of data generated in contemporary bioscience, and thereby to turn them into knowledge and information. These data hold the key to tackling some of our most pressing challenges such as feeding an expanding world population, coping with climate change and providing new, high-efficacy therapeutics with minimal side effects. The UK will now be at the hub of an exciting European partnership to accelerate the application of science in these and other areas."

For further information, please visit:
http://www.ebi.ac.uk

About EMBL-EBI
The European Bioinformatics Institute (EBI) is a non-profit academic organisation that forms part of the European Molecular Biology Laboratory (EMBL).

The EBI is a centre for research and services in bioinformatics. The Institute manages databases of biological data including nucleic acid, protein sequences and macromolecular structures.

Most Popular Now

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...